Cassava Sciences Inc vs PayPal Holdings, Inc. — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while PayPal Holdings, Inc. trades at $55.44 (market cap $47.07B). The key difference: PayPal Holdings, Inc. is far larger — about 1194.7× Cassava Sciences Inc's market cap, and PayPal Holdings, Inc. pays a 1.02% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and PayPal Holdings, Inc. for 106 Days on average.
| FLNA | PYPL | |
|---|---|---|
Market Cap | $39.40M | $47.07B |
Volume | 759,018 | 13,860,099 |
Sector | Health | Financials |
52-Week High | $4.64 | $75.75 |
52-Week Low | $0.68 | $39.08 |
Typical Hold Time | 37 Days | 106 Days |
Enterprise Value | -$43.28M | $49.21B |
Dividend Yield | — | 1.02% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
PayPal (PYPL) trades at $55.47, up 0.95% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 10.4, net income margin of 14.36%, and consistent revenue growth from $33.17B in 2025 to $34.1B projected for 2026. Recent positive developments include a Meta partnership for AI-powered checkout and three consecutive quarterly earnings beats.
PYPL presents a compelling value opportunity with attractive valuation multiples and solid profitability, though investors face risks from checkout competition and slowing growth. Analyst consensus leans cautious with 60% hold ratings, but the $56.41 price target suggests modest upside potential from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →